Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Drug marketers to take...

    Drug marketers to take onus for quality of drugs, regulatory compliance: Health Ministry Gazette

    Farhat NasimWritten by Farhat Nasim Published On 2020-02-19T14:40:47+05:30  |  Updated On 19 Feb 2020 2:40 PM IST
    Drug marketers to take onus for quality of drugs, regulatory compliance: Health Ministry Gazette

    New Delhi: Through a recent gazette notification, the Union Health Ministry has amended the Drugs and Cosmetics Rules, 1945, wherein, drug marketers along with the manufacturers will be equally responsible for the quality, efficacy and other regulatory compliance for the drugs sold or distributed by them. This will come into effect from March 1 2021.

    The move calls for equal distribution of the responsibilities right from its manufacture, market and sale till the time it reached the public; both the manufacture and the marketer will be accountable for the quality of drugs. Moreover, the name of the marketer has to be shown on the container.

    Prior to the amendment, the Health Ministry had circulated a draft of the same in the public domain, seeking suggestions and objections. Objections and suggestions were received and considered by the Government.

    Also Read: Drug Marketers As Liable As Drug Manufacturers For Quality, Efficacy, Regulatory Compliance: Health Ministry Issues Draft

    Thereafter, in exercise of the powers conferred under sections 12 and 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government, after consultation with the Drugs Technical Advisory Board (DTAB) made certain amends to the Drugs and Cosmetics Rules, 1945. The amendments broaden the onus of manufacturing and distributing drugs by setting transparency via clear mention of the individual's name on the drug distributed. In this regard, a revised definition of "Marketer" has been inserted in the said rule as;

    '(ea) "Marketer" means a person who as an agent or in any other capacity adopts any drug manufactured by another manufacturer under an agreement for the marketing of such drug by labelling or affixing his name on the label of the drug with a view for its sale and distribution;

    The gazette notification further mentions about another integral amendment that holds drug marketer responsible for the quality of drugs they distribute. For this, ' Agreement for marketing' after rule 84C has been inserted in the said rule that read;

    "84D. Agreement for marketing.- No marketer shall adopt any drug manufactured by another manufacturer for the marketing of such drug by labelling or affixing his name on the label of the drug with a view for its sale and distribution without an agreement as referred to in clause (ea) of rule 2.

    84E. Responsibility of marketer of the drugs.- Any marketer who sells or distributes any drug shall be responsible for the quality of that drug as well as other regulatory compliances along with the manufacturer under these rules.".

    Further, in rule 96, after sub-clause (xii) of clause (1), the following sub-clause shall be inserted, namely:―

    "(xiii) The name of the marketer of the drug and its address, in case the drug is marketed by a marketer: Provided that if the drug is contained in an ampoule or a similar small container, it shall be enough if only the name of the marketer is shown.".

    For further detail click on the link below;

    https://business.medicaldialogues.in/pdf_upload/pdf_upload-124417.pdf
    cdscohealth ministrydrug manufacturersdrug marketersdrugs and cosmetics rule

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok